- ISIN
- US3968791083
- CUSIP
- 396879108
- Sector
- Healthcare
- Industry
- Biotechnology
- IPO Date
- Sep 25, 2020
Highlights
- Market Cap
- $198.16M
- Enterprise Value
- $187.65M
- EPS (TTM)
- -$1.56
- Total Revenue (TTM)
- $3.56K
- Gross Profit (TTM)
- $903.00
- EBITDA (TTM)
- -$21.89M
- Year Range
- $7.78 - $34.10
- Target Price
- $50.00
- ROA (TTM)
- -207.10%
- ROE (TTM)
- -412.83%
- Avg. Volume (1M)
- 178K
- Avg. Volume Value (1M)
- $2.86M
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
GLSI Performance Chart
Greenwich LifeSciences, Inc. (GLSI) is down 35.7% since the beginning of the year. At $14 per share, GLSI is trading 60.4% below its 52-week high of $34. Investors who bought $1,000 worth of GLSI shares 5 years ago would now be looking at an investment worth $342.
Loading charts...
Compare this symbol against anything
Returns By Period
Greenwich LifeSciences, Inc. (GLSI) has returned -35.74% so far this year and 21.73% over the past 12 months.
Greenwich LifeSciences, Inc.
- 1D
- -3.71%
- 1M
- -38.64%
- 6M
- -55.10%
- YTD
- -35.74%
- 1Y
- 21.73%
- 3Y*
- 10.93%
- 5Y*
- -19.31%
- 10Y*
- —
- ALL TIME*
- 15.72%
Benchmark (S&P 500 Index)
- 1D
- 0.70%
- 1M
- 0.09%
- 6M
- 7.94%
- YTD
- 9.41%
- 1Y
- 20.07%
- 3Y*
- 17.84%
- 5Y*
- 11.25%
- 10Y*
- 13.26%
- ALL TIME*
- 8.09%
GLSI Monthly Returns History
Based on dividend-adjusted daily data since Sep 25, 2020, GLSI's average daily return is +0.72%, while the average monthly return is +9.61%. At this rate, an investment would double in approximately 0.6 years.
Historically, 41% of months were positive and 59% were negative. The best month was Dec 2020 with a return of +588.1%, while the worst month was Jul 2026 at -42.5%. The longest winning streak lasted 3 consecutive months, and the longest losing streak was 5 months.
On a daily basis, GLSI closed higher 47% of trading days. The best single day was Dec 9, 2020 with a return of +998.4%, while the worst single day was Apr 12, 2021 at -27.0%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 43.12% | -7.82% | -13.35% | -1.67% | 10.82% | -10.37% | -42.46% | -35.74% | |||||
| 2025 | 15.23% | -5.56% | -21.93% | 5.87% | -2.48% | -7.92% | 20.62% | 4.94% | -13.33% | -7.44% | -5.21% | 140.66% | 87.09% |
| 2024 | -17.87% | 40.74% | 63.98% | -37.71% | 19.40% | 16.39% | -6.60% | -13.03% | 2.50% | -6.40% | 5.95% | -21.19% | 6.75% |
| 2023 | 30.53% | -21.32% | -11.66% | -22.34% | 1.68% | -11.43% | -4.61% | -0.33% | -3.60% | -5.43% | 39.95% | -10.09% | -30.79% |
| 2022 | -24.09% | 5.52% | 0.67% | -39.60% | -34.68% | 9.43% | -4.49% | 17.18% | -4.01% | -0.99% | 54.83% | 8.96% | -37.53% |
| 2021 | 2.82% | -16.45% | 8.81% | 10.30% | -1.38% | 21.20% | -12.17% | 1.39% | -2.37% | -9.50% | -11.11% | -22.59% | -33.29% |
Benchmark Metrics
Greenwich LifeSciences, Inc. has an annualized alpha of 442.38%, beta of 0.80, and R2 of 0.00 versus S&P 500 Index. Calculated based on daily prices since September 25, 2020.
- This stock captured 210.23% of S&P 500 Index gains and 184.77% of its losses - amplifying both gains and losses, but participating more in upside than downside.
- R2 of 0.00 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- 442.38%
- Beta
- 0.80
- R²
- 0.00
- Upside Capture
- 210.23%
- Downside Capture
- 184.77%
Return for Risk
Risk / Return Rank
GLSI ranks 57 for risk / return — above 57% of stocks peers on PortfoliosLab. Its historical combined result is near the middle of the peer group.
Risk / Return Metrics
The table below present risk-adjusted performance metrics for Greenwich LifeSciences, Inc. (GLSI) and compare them to S&P 500 Index.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| GLSI | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -1.18 | ||
| Sortino ratioReturn per unit of downside risk | -0.89 | ||
| Omega ratioGain probability vs. loss probability | 1.13 | 1.25 | -0.13 |
| Calmar ratioReturn relative to maximum drawdown | 0.38 | 2.00 | -1.62 |
| Martin ratioReturn relative to average drawdown | 0.89 | 8.49 | -7.60 |
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the Greenwich LifeSciences, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Greenwich LifeSciences, Inc. was 90.11%, occurring on Jun 16, 2022. The portfolio has not yet recovered.
The current Greenwich LifeSciences, Inc. drawdown is 81.31%.
Drawdown | Fall | Recovery | Underwater | Related event |
|---|---|---|---|---|
-90.11%Jun 2022 | 1y 6mo | — | 5y 7moDec 2020 - now | Bear market2022 |
-39.57%Nov 2020 | 1mo 19d | 26d | 2mo 15dSep 2020 - Dec 2020 | — |
Drawdown Indicators
| GLSI | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -90.11% | -56.78% | -33.33% |
Max Drawdown (1Y)Largest decline over 1 year | -61.87% | -9.10% | -52.77% |
Max Drawdown (3Y)Largest decline over 3 years | -61.87% | -18.90% | -42.97% |
Max Drawdown (5Y)Largest decline over 5 years | -84.52% | -25.43% | -59.09% |
Max Drawdown (10Y)Largest decline over 10 years | — | -33.92% | — |
Current DrawdownCurrent decline from peak | -81.31% | -1.58% | -79.73% |
Average DrawdownAverage peak-to-trough decline | -72.80% | -10.70% | -62.10% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 26.24% | 2.14% | +24.10% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Greenwich LifeSciences, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how Greenwich LifeSciences, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for GLSI relative to other companies in the Biotechnology industry. Currently, GLSI has a P/S ratio of 52,927.5. This P/S ratio is high relative to other companies in the industry. It could mean the stock is overvalued, or that investors expect strong future growth and profitability.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for GLSI in comparison with other companies in the Biotechnology industry. Currently, GLSI has a P/B value of 37.3. This P/B ratio is higher than most companies in the industry. It may suggest the stock is overvalued or that investors expect the company to generate high returns on its assets.
Income Statement
| TTM | |
|---|---|
Revenue | |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with GLSI
Add Greenwich LifeSciences, Inc. to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with GLSI